904929-24-4

Usage

Uses

Used in Pharmaceutical Research:
3-bromo-6,7-dihydro-8(5H)-Quinolinone is used as a building block for the synthesis of more complex organic molecules in drug discovery and development. It has potential applications in the study of biological activity and molecular interactions, which is important for understanding the properties and reactivity of quinolinone derivatives.
Used in Agrochemical Research:
3-bromo-6,7-dihydro-8(5H)-Quinolinone is also used as a building block in the synthesis of more complex organic molecules in agrochemical research. It aids in the design and synthesis of new compounds with desired pharmacological or biological effects, contributing to the development of effective agrochemicals.

Upstream product

• 904929-22-2 3-bromo-5,6,7,8-tetrahydroquinolin-8-yl acetate 
• 904929-21-1 3-bromo-5,6,7,8-tetrahydroquinoline-1-oxide 
• 1256360-50-5 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6,7,8-tetrahydroquinoline 
• 10500-57-9 5,6,7,8-tetrahydroquinoline 
• 904929-23-3 3-bromo-5,6,7,8-tetrahydroquinolin-8-ol 
• 82132-68-1 3-bromo-5,6,7,8-tetrahydroquinoline 

Downstream Products

• 904929-26-6 C₁₅H₁₁Cl₂NO₂ 

Relevant academic research and scientific papers

Cyclic gyrase and topoisomerase IV inhibitor

The invention belongs to the technical field of medicament, and particularly relates to a compound shown in formula (I) (please see the formula (I) in the description), and acceptable salt, ester or stereoisomer of the compound in pharmacy. R1, R2, a ring

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

ANTIDIABETIC BICYCLIC COMPOUNDS

Bicyclic compounds containing a fused pyridine ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 d